In the past week, HOOK stock has gone up by 33.10%, with a monthly gain of 32.16% and a quarterly surge of 49.37%. The volatility ratio for the week is 15.95%, and the volatility levels for the last 30 days are 11.42% for Hookipa Pharma Inc The simple moving average for the last 20 days is 19.74% for HOOK stock, with a simple moving average of 40.19% for the last 200 days.
Is It Worth Investing in Hookipa Pharma Inc (NASDAQ: HOOK) Right Now?
The 36-month beta value for HOOK is at 0.94. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HOOK is 70.40M, and currently, shorts hold a 0.45% of that float. The average trading volume for HOOK on April 30, 2024 was 779.40K shares.
HOOK) stock’s latest price update
Hookipa Pharma Inc (NASDAQ: HOOK)’s stock price has increased by 5.34 compared to its previous closing price of 0.89. However, the company has seen a 33.10% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-04-22 that Hookipa Pharma is conducting a call on 04/25/24 to share lead asset HB-200’s pivotal trial design. A Phase 2a clinical update is due in 2Q’24. The company’s shares closed at $0.733, with a valuation of approximately $72.53. Positive data could push shares up 3-5x while negative news could cut the stock in half or worse. Hookipa’s partnership with Gilead provides financial support for its lead asset allowing the company to focus on its pivotal-ready program.
Analysts’ Opinion of HOOK
Many brokerage firms have already submitted their reports for HOOK stocks, with BofA Securities repeating the rating for HOOK by listing it as a “Underperform.” The predicted price for HOOK in the upcoming period, according to BofA Securities is $0.50 based on the research report published on December 02, 2022 of the previous year 2022.
Morgan Stanley gave a rating of “Equal-Weight” to HOOK, setting the target price at $6 in the report published on November 12th of the previous year.
HOOK Trading at 25.80% from the 50-Day Moving Average
After a stumble in the market that brought HOOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.10% of loss for the given period.
Volatility was left at 11.42%, however, over the last 30 days, the volatility rate increased by 15.95%, as shares surge +30.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.58% upper at present.
During the last 5 trading sessions, HOOK rose by +33.10%, which changed the moving average for the period of 200-days by +3.25% in comparison to the 20-day moving average, which settled at $0.7968. In addition, Hookipa Pharma Inc saw 16.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HOOK starting from Kandera Reinhard, who purchase 7,000 shares at the price of $0.72 back on Aug 21 ’23. After this action, Kandera Reinhard now owns 43,092 shares of Hookipa Pharma Inc, valued at $5,075 using the latest closing price.
Kandera Reinhard, the Chief Financial Officer of Hookipa Pharma Inc, purchase 8,000 shares at $0.71 during a trade that took place back on Aug 16 ’23, which means that Kandera Reinhard is holding 36,092 shares at $5,712 based on the most recent closing price.
Stock Fundamentals for HOOK
Current profitability levels for the company are sitting at:
- -4.22 for the present operating margin
- 0.82 for the gross margin
The net margin for Hookipa Pharma Inc stands at -4.06. The total capital return value is set at -0.71. Equity return is now at value -84.81, with -49.18 for asset returns.
Based on Hookipa Pharma Inc (HOOK), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -8.77. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -387.8.
Currently, EBITDA for the company is -81.38 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of -0.98. The receivables turnover for the company is 1.04for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.
Conclusion
In conclusion, Hookipa Pharma Inc (HOOK) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
